Merck’s Keytruda has received FDA approval to expand its use in lung cancer

The US Food and Drug Administration has approved the expanded use of Merck & Co’s blockbuster immunotherapy Keytruda in early-stage patients with non-small cell lung cancer who can have their tumours surgically removed.

Share This Post:

POPULAR POSTS
FOLLOW US
Like Us On Facebook
Follow Us On Twitter
Subscribe To Our Channel
TikTok
LIVE STREAM